Cationic Lipid Complex for Nucleic Acid Delivery Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for nucleic acid delivery face challenges such as instability leading to particle aggregation during storage and inefficient release of nucleic acids into the cytoplasm, as well as difficulties in traversing the cell membrane and stability in blood plasma.
Innovation Solution
A novel cationic lipid compound represented by specific formulae, which forms a lipid complex with nucleic acids and includes a combination of neutral lipids, polyethylene glycol-modified lipids, and sterols, enhancing stability and delivery efficiency by preventing particle aggregation and facilitating effective release into the cytoplasm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipids are used for nucleic acid delivery, then nucleic acid encapsulation and cell membrane penetration are improved, but particle aggregation occurs during storage and delivery efficiency to cytoplasm is reduced
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the introduction of hydrophilic groups (e.g., carboxylic acid groups) and adjustment of alkyl chain lengths. This structural parameter change allows the lipid to maintain cationic charge for nucleic acid binding while incorporating features that prevent aggregation during storage, thus resolving the contradiction between stability in plasma and resistance to aggregation.
Solution Approach 2:
The patent creates composite lipid structures that combine hydrophobic regions (for membrane interaction) with hydrophilic regions (for stability in aqueous environments and prevention of aggregation). This composite structure enables the lipid to function effectively in both storage and delivery conditions, addressing the contradiction between maintaining particle stability and preventing aggregation.
2Reliability
If cationic lipids are used to protect siRNA from RNase decomposition, then stability in blood plasma is improved, but release efficiency into cytoplasm is reduced
Solution Approach 1:
The patent designs cationic lipids with dynamic properties that allow them to maintain stable complexes with nucleic acids during circulation (protecting from RNase) but undergo conformational changes or interactions under specific cellular conditions that facilitate release into the cytoplasm. This dynamic behavior resolves the contradiction between protection stability and release efficiency.
Solution Approach 2:
The patent introduces chemical parameter changes in the lipid structure, such as incorporating pH-sensitive groups or adjusting charge density, that allow the lipid-nucleic acid complex to remain stable in blood plasma but change properties upon cellular uptake, enabling efficient release into the cytoplasm. This parameter modification resolves the contradiction between protection and delivery efficiency.
3Ease of operation
If conventional cationic lipids are used for nucleic acid delivery, then cell membrane penetration is improved, but biodegradability is poor
Solution Approach 1:
The patent modifies the chemical parameters of cationic lipids by incorporating biodegradable linkages (such as ester bonds or amide bonds) while maintaining the cationic charge necessary for cell membrane penetration. This parameter change allows the lipid to fulfill its delivery function while being metabolically degraded after use, resolving the contradiction between penetration efficiency and biodegradability.
Solution Approach 2:
The patent creates composite lipid structures that combine membrane-penetrating moieties with biodegradable components. The hydrophobic regions facilitate membrane interaction and penetration, while the hydrophilic regions incorporate biodegradable bonds that allow enzymatic breakdown. This composite design resolves the contradiction between penetration capability and biodegradability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipid complex maintains physical stability over time, prevents particle diameter increase during storage, and effectively releases nucleic acids into the cytoplasm, addressing issues of aggregation and delivery efficiency.
Implementation Method 1
lipid complex containing: (I) the compound according to any one of [1] to 11] and 2a] to 2e] or a pharmaceutically acceptable salt thereof; and (II) at least one lipid selected from the group consisting of a neutral lipid, a polyethylene glycol-modified lipid and a sterol
Implementation Method 2
a method for preventing aggregation by adding polyethylene glycol-modified lipids (PEG lipids) to the fine particles
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 independently represent an alkylene group having 3 to 10 carbon atoms; R1 and R2 independently represent an alkyl group having 4 to 24 carbon atoms or an alkenyl group having 4 to 24 carbon atoms; R3 represents an alkyl group having 1 to 3 carbon atoms; and X1 represents a single bond or CO-O-.